Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

Researchers at ACC's annual meeting reported first-in-human data from a clinical trial of TN-201 that suggested symptom improvement.

The firm's artificial intelligence-based biomarker tools including Lunit Scope IO and Lunit Scope Universal IHC will be available across trials at the Center for Cancer Research.

The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.

The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.

The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.